• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急性和复发性心包炎病理生理学的最新进展。

An update on the pathophysiology of acute and recurrent pericarditis.

机构信息

Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Pauley Heart Center, Richmond, VA, USA -

Department of Internal Medicine, First Clinic of Internal Medicine, University of Genoa, Genoa, Italy -

出版信息

Panminerva Med. 2021 Sep;63(3):249-260. doi: 10.23736/S0031-0808.20.04205-6. Epub 2020 Dec 18.

DOI:10.23736/S0031-0808.20.04205-6
PMID:33337127
Abstract

INTRODUCTION

Pericarditis is an inflammatory disease of the pericardium. Progress has been done in recent years in the understanding of its pathophysiology. In particular, preclinical and clinical studies have contributed to increasing our knowledge on the role of interleukin (IL)-1 and NLRP3 (NACHT, leucine-rich repeat, and pyrin domain-containing protein 3) inflammasome.

EVIDENCE ACQUISITION

Information for this study has been retrieved in original articles, reviews, systematic reviews, and meta-analyses identified through PubMed using the following search terms (or combination of terms): "pericarditis," "acute pericarditis," "recurrent pericarditis," "idiopathic recurrent acute pericarditis," "autoimmunity," "autoinflammation," "outcomes." Only articles published in English were included. Additional papers identified from the reference list of the retrieved articles were also considered.

EVIDENCE SYNTHESIS

Based on current evidence, pericarditis should be considered as an inflammatory reaction to various stimuli, including chemical/physical, infectious, or ischemic ones, with a viral infection being a common etiology. Interaction of pathogens or irritants with toll-like receptor (TLRs) and stimulation of IL-1 receptor by IL-1α and IL-1β leads to an increased transcription of proinflammatory genes, including those needed for NLRP3 inflammasome assembly. This pathway is confirmed indirectly by the beneficial effect of colchicine (an indirect NLRP3 inflammasome inhibitor) and IL-1 blockers in patients with recurrent pericarditis. More recently, a direct evidence of the NLRP3 inflammasome within the inflamed pericardium has been provided as well. It may, however, occur that self-antigens on the surface of mesothelial cells or microbial peptides may stimulate autoreactive T cells along with B cells producing antiheart antibodies, although less evidence is available on this.

CONCLUSIONS

Some uncertainties still remain about the role of neutrophils, neutrophil extracellular traps (NETs), and pericardial interstitial cells in recurrent and constrictive pericarditis. Unraveling these aspects might have a direct impact on the development of novel targeted therapies, especially considering the increasing number of drugs targeting NETs.

摘要

简介

心包炎是一种心包的炎症性疾病。近年来,在心包炎的病理生理学方面取得了进展。特别是,临床前和临床研究使我们对白细胞介素 (IL)-1 和 NLRP3(NACHT、富含亮氨酸重复和 pyrin 结构域蛋白 3)炎性体的作用有了更多的了解。

证据获取

通过使用以下搜索词(或搜索词组合)在 PubMed 中检索原始文章、综述、系统综述和荟萃分析,获取了这项研究的信息:“心包炎”、“急性心包炎”、“复发性心包炎”、“特发性复发性急性心包炎”、“自身免疫”、“自身炎症”、“结局”。只纳入发表在英语中的文章。还考虑了从检索到的文章的参考文献中确定的其他论文。

证据综合

根据目前的证据,心包炎应被视为对各种刺激的炎症反应,包括化学/物理、感染或缺血性刺激,病毒感染是常见病因。病原体或刺激物与 toll 样受体 (TLR) 的相互作用以及 IL-1α 和 IL-1β 对 IL-1 受体的刺激导致前炎性基因的转录增加,包括 NLRP3 炎性体组装所需的基因。秋水仙碱(间接 NLRP3 炎性体抑制剂)和 IL-1 阻滞剂在复发性心包炎患者中的有益作用间接证实了这一途径。最近,还提供了炎症性心包内 NLRP3 炎性体的直接证据。然而,可能存在这样的情况,即表面间皮细胞上的自身抗原或微生物肽可能刺激自身反应性 T 细胞和产生抗心脏抗体的 B 细胞,尽管关于这方面的证据较少。

结论

关于中性粒细胞、中性粒细胞胞外陷阱 (NETs) 和心包间质细胞在复发性和缩窄性心包炎中的作用仍存在一些不确定性。阐明这些方面可能会对新型靶向治疗的发展产生直接影响,特别是考虑到针对 NETs 的药物数量不断增加。

相似文献

1
An update on the pathophysiology of acute and recurrent pericarditis.急性和复发性心包炎病理生理学的最新进展。
Panminerva Med. 2021 Sep;63(3):249-260. doi: 10.23736/S0031-0808.20.04205-6. Epub 2020 Dec 18.
2
Interleukin-1 and the NLRP3 Inflammasome in Pericardial Disease.白细胞介素-1 和 NLRP3 炎性小体在心包疾病中的作用。
Curr Cardiol Rep. 2021 Oct 1;23(11):157. doi: 10.1007/s11886-021-01589-x.
3
Advances in pharmacotherapy for acute and recurrent pericarditis.急性和复发性心包炎的药物治疗进展。
Expert Opin Pharmacother. 2022 Apr;23(6):681-691. doi: 10.1080/14656566.2022.2054327. Epub 2022 Mar 20.
4
Recurrent Pericarditis: a Stubborn Opponent Meets New Treatments in 2022.2022 年,复发性心包炎:顽固对手遭遇新疗法。
Curr Cardiol Rep. 2022 Aug;24(8):915-923. doi: 10.1007/s11886-022-01719-z. Epub 2022 May 25.
5
Pathogenic pathways and therapeutic targets of inflammation in heart diseases: A focus on Interleukin-1.心脏疾病中炎症的致病途径和治疗靶点:聚焦于白细胞介素-1。
Eur J Clin Invest. 2024 Feb;54(2):e14110. doi: 10.1111/eci.14110. Epub 2023 Oct 14.
6
Novel Pathophysiological, Diagnostic and Therapeutic Concepts in Acute and Recurrent Pericarditis.急性和复发性心包炎的新型病理生理、诊断和治疗概念
Rev Cardiovasc Med. 2023 Mar 3;24(3):77. doi: 10.31083/j.rcm2403077. eCollection 2023 Mar.
7
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.白细胞介素-1 和炎症小体作为心血管疾病的治疗靶点。
Circ Res. 2020 Apr 24;126(9):1260-1280. doi: 10.1161/CIRCRESAHA.120.315937. Epub 2020 Apr 23.
8
Novel Therapeutic Insights Into the Treatment of Pericarditis: Targeting the Innate Immune System.心包炎治疗的新治疗见解:靶向固有免疫系统。
J Cardiovasc Pharmacol. 2024 May 1;83(5):377-383. doi: 10.1097/FJC.0000000000001553.
9
Regulation and Function of the Nucleotide Binding Domain Leucine-Rich Repeat-Containing Receptor, Pyrin Domain-Containing-3 Inflammasome in Lung Disease.含核苷酸结合结构域富含亮氨酸重复序列受体、含吡啉结构域的3炎性小体在肺部疾病中的调控与功能
Am J Respir Cell Mol Biol. 2016 Feb;54(2):151-60. doi: 10.1165/rcmb.2015-0231TR.
10
The inflammasome as a therapeutic target for myopericardial diseases.炎症小体作为心肌疾病的治疗靶点。
Minerva Cardiol Angiol. 2022 Apr;70(2):238-247. doi: 10.23736/S2724-5683.21.05876-2.

引用本文的文献

1
A Combined Approach to the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery.心脏手术中预防术后房颤的联合方法
Biomedicines. 2025 Aug 17;13(8):1999. doi: 10.3390/biomedicines13081999.
2
Update for diagnosis and treatment of syndrome after cardiac injury: a mini-review.心脏损伤后综合征的诊断与治疗进展:一篇综述
Front Cardiovasc Med. 2025 Feb 5;12:1526671. doi: 10.3389/fcvm.2025.1526671. eCollection 2025.
3
[Colchicine-Phoenix from the ashes].[秋水仙碱——浴火重生]
Wien Klin Wochenschr. 2025 Feb;137(Suppl 1):1-33. doi: 10.1007/s00508-024-02490-7. Epub 2025 Feb 6.
4
Advances in the Multimodality Imaging and Management of Recurrent Pericarditis: A Contemporary Review.复发性心包炎的多模态成像与管理进展:当代综述
Curr Cardiol Rep. 2024 Dec;26(12):1359-1375. doi: 10.1007/s11886-024-02133-3. Epub 2024 Sep 20.
5
Novel Pathophysiological, Diagnostic and Therapeutic Concepts in Acute and Recurrent Pericarditis.急性和复发性心包炎的新型病理生理、诊断和治疗概念
Rev Cardiovasc Med. 2023 Mar 3;24(3):77. doi: 10.31083/j.rcm2403077. eCollection 2023 Mar.
6
Deciphering the Basis of Molecular Biology of Selected Cardiovascular Diseases: A View on Network Medicine.解析选定心血管疾病的分子生物学基础:网络医学视角。
Int J Mol Sci. 2022 Sep 28;23(19):11421. doi: 10.3390/ijms231911421.
7
NLRP3-mediated inflammation in cardio-oncology: sterile yet harmful.NLRP3 介导体细胞肿瘤心脏病学中的炎症:无菌但有害。
Transl Res. 2023 Feb;252:9-20. doi: 10.1016/j.trsl.2022.08.004. Epub 2022 Aug 7.
8
Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation.秋水仙碱治疗 COVID-19:靶向 NLRP3 炎症小体以抑制过度炎症反应。
Inflamm Res. 2022 Mar;71(3):293-307. doi: 10.1007/s00011-022-01540-y. Epub 2022 Feb 3.
9
Post-cardiac injury syndrome triggered by radiofrequency ablation for AVNRT.射频消融治疗房室结折返性心动过速致心脏损伤后综合征。
BMC Cardiovasc Disord. 2021 Dec 25;21(1):611. doi: 10.1186/s12872-021-02436-1.
10
Interleukin-1 and the NLRP3 Inflammasome in Pericardial Disease.白细胞介素-1 和 NLRP3 炎性小体在心包疾病中的作用。
Curr Cardiol Rep. 2021 Oct 1;23(11):157. doi: 10.1007/s11886-021-01589-x.